N. Engl. J. Med. 2019 Sep 28
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Abstract
Background
In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC.
Methods
In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more.
Results
Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P = 0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy.
Conclusions
First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).
Related Questions
Would you consider using IO alone for lung cancer patients with PD-L1 <1% but who have high TMB?
The brief answer here is a resounding no. A more extended version might include a statement that this would be a case of not seeing the forest for the trees.And the tree here is the FDA approval of pembrolizumab in a tissue-agnostic fashion for patients with advanced TMB >10 mutations/Mbase- likely ...
In what situations would immunotherapy alone be appropriate for non-metastatic NSCLC?
Based on our current SOC treatment paradigms for patients who don't have contraindications to definitive treatment options, my short answer would be no. However, few caveats to that no as always. Few examples where I think this would be an appropriate approach based on currently available data. Poor...
What are best practices for oncologists during the national platinum shortage?
In breast cancer, we are prioritizing patients with curable disease in which platinum agents are a critical part of the regimen or have actually shown a clear advantage (the only example of this is shown below in bold).Use an alternative to a carboplatin-based regimen whenever possible. If no altern...
What is your approach and preferred first line treatment regimen for advanced/metastatic adenosquamous NSCLC?
As with all advanced lung cancer, the answer to this question depends upon molecular characteristics and PDL1 status. I would perform NGS (next generation sequencing) analysis of all adenosquamous cancers (by tissue, and if uninformative, potentially ctDNA testing) as well as PDL1. As I tell all of ...
How would use of adjuvant atezolizumab for PDL1+ NSCLC potentially impact your treatment choice at recurrence?
Certainly pattern of relapse is important, and those with local or locoregional recurrences could be treated with definitive intent SBRT, surgery, or concurrent chemotherapy and radiation for mediastinal recurrence. For those with recurrent not amenable to local therapy, this is a challenging questi...
What factors do you take into account for recommending chemo/IO vs IO/IO vs CheckMate 9LA regimen in front line therapy for PD-L1 negative advanced squamous cell carcinoma?
As others have noted, the HR for the squamous subset of NSCLC seems to suggest that these patients benefit most from combined ICI, seen in both the CM227 and 9LA studies (with the caveat that comparator is chemotherapy alone which is now outdated.) In CM227, the HR for nivo-ipi vs chemo was 0.53 in ...
When determining frontline treatment for NSCLC, would you incorporate molecular predictors of resistance to immunotherapy such as STK11, KEAP1, p53?
This is a great question and there are a number of first line trials that I hope will be able to answer this. I do believe that we should be evaluating these patients specifically for trials (i.e., NCT04265534). I also think looking at these data across the current studies including CM227 and 9LA wi...
What is your preferred first line regimen for PDL1-negative squamous cell lung cancer?
Firstly, I think clinical trials, where available, should be considered for all patients particularly those with squamous and/or PD-L1 negative tumors as the benefits from chemo-IO in this setting have not been as striking as in PD-L1 positive or non squamous tumors, we have more work to do to impro...
Are there any data for second line nivolumab-ipilimumab in patients with metastatic NSCLC treated with either single agent pembrolizumab or chemotherapy + ICI as first line therapy?
Resistance to PD-(L)1 inhibitor based first line therapy and choice of subsequent treatment for patients with advanced NSCLC is an ongoing challenge. While addition of CTLA-4 inhibitor to PD-1 inhibitor has shown additive anti-tumor activity via complementary mechanisms of action, it is currently un...
How do you decide between checkpoint monotherapy versus chemo-immunotherapy approach for patients with PD-L1 High (>50%) NSCLC?
At this point, there are no prospective trials comparing checkpoint monotherapy and chemo-immunotherapy for patients with PD-L1 high NSCLC. The ongoing prospective INSIGNA trial will answer this question. If one does a cross trial comparison of pembrolizumab for patients with PD-L1 of >50% and chemo...
Are you selecting any specific patient cohort with metastatic NSCLC for treatment with the CheckMate 9LA protocol of ipilimumab + nivolumab + 2 cycles of chemotherapy?
When looking at potential subgroups that might benefit from the CheckMate 9LA regimen, I consider patients with squamous cell carcinoma, where the HR was 0.63; PD-L1 less than 1%, which demonstrated similar 2y OS to those with PD-L1> 1%. Another intriguing group is patients with brain metastases whe...
Is there any evidence that patients with metastatic NSCLC with KRAS G12C mutations benefit less from treatment with immunotherapy?
KRAS mutation in NSCLC has been associated with improved response rate and overall survival compared to KRAS wild type NSCLC in meta-analysis of single-agent, second-line trials with PD-1/PD-L1 inhibition. Moreover, analysis of patients with KRAS lung adenocarcinoma divided by subsets including co-m...
How do you proceed with treatment of a patient with stage IIIB NSCLC who progresses DURING treatment with concurrent weekly carboplatin/paclitaxel and radiation?
I have been looking at this question for a little over a week, and struggling to know how to answer this. The relevant trials for a patient with PDL1 somewhere between 0 and 49% (KEYNOTE-189, KEYNOTE-407, KEYNOTE-042, CheckMate 227, and 9LA) would have excluded patients who received either adjuvant ...
How do the results of CheckMate 9LA and subsequent FDA approval of nivo+ipi+chemo impact your first line management of patients with non-small cell lung cancer?
As many have pointed out, the control arm is no longer SOC and this just adds to numerous ‘me too‘ regimens in frontline non driver mutation NSCLC- atezolizumab, nivo/ipi alone to name a few. It will not greatly impact current practice. If this leads to a price war and brings down the cost of drugs,...
Would you consider checkpoint inhibitor therapy alone in a patient with metastatic NSCLC with PDL-1 < 1% who is otherwise refusing chemotherapy?
I would not personally recommend a checkpoint inhibitor in the first line setting of a PDL1 negative metastatic NSCLC. I think genomic analysis would help guide that decision as well. For example, the presence of an STK11 mutation would make me even more hesitant to recommend a single agent checkpoi...